01—Abstract
Summary
Summary of the 8-K filed May 7, 2025. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported first-quarter 2025 results, with total revenue of $984.2 milliona, down 2.7% from $1,011.6 million in the first quarter of 2024.
Organic revenue decreased 1.8%, with declines in all three business segments. GAAP net income available to common shareholders was $25.5 millionb, or $0.50 per diluted share, compared with $1.30 per diluted share a year earlier. The GAAP decline was driven by lower revenue and accelerated amortization of certain CDMO client relationships, which raised amortization of intangible assets to $65.3 million from $32.6 million.
Non-GAAP diluted EPS was $2.34c, up 3.1% from $2.27, helped mainly by lower tax rates, interest expense and diluted share count. The company increased its 2025 guidance, now projecting reported revenue decline of (5.5)% to (3.5)% and GAAP EPS of $4.35 to $4.85, versus prior ranges of (7.0)% to (4.5)% and $4.30 to $4.80. Non-GAAP EPS guidance rose to $9.30 to $9.80 from $9.10 to $9.60.
Management attributed the raise primarily to improved DSA net bookings in the first quarter, which are expected to add DSA revenue this year, particularly in the first half. CEO James C. Foster described the quarter as showing signs of demand stabilization, with DSA bookings at their highest level in two years, while maintaining a balanced yet cautious outlook.
Capital allocation was active: the company repurchased 2.1 million shares for $350.0 milliond in the quarter and had $549.3 million remaining under its $1.0 billion authorization as of March 29, 2025. Long-term debt, net and finance leases rose to $2.51 billion from $2.24 billion at year-end 2024. The filing also notes ongoing third-party legal costs in the DSA segment tied to U.S. government investigations into the NHP supply chain, which the company excludes from non-GAAP results.
02—Key points
Key Highlights
- Total revenue of $984.2 million, down 2.7% year over year; organic revenue down 1.8%, with declines across RMS, DSA and Manufacturing Solutions.
- GAAP diluted EPS of $0.50 versus $1.30 a year earlier; GAAP operating margin fell to 7.6% from 12.5%, mainly due to $65.3 million of amortization including accelerated amortization of CDMO client relationships.
- Non-GAAP diluted EPS of $2.34, up 3.1% from $2.27, driven by lower tax rate, interest expense and diluted shares; non-GAAP operating margin rose to 19.1% from 18.5%.
- 2025 guidance raised: reported revenue growth of (5.5)% to (3.5)% (from (7.0)% to (4.5)%) and non-GAAP EPS of $9.30 to $9.80 (from $9.10 to $9.60).
- DSA net bookings reached their highest level in two years in the quarter, expected to add incremental DSA revenue, particularly in the first half of 2025.
- Repurchased $350.0 million of common stock (2.1 million shares) in Q1 2025, with $549.3 million remaining under the $1.0 billion authorization.
- Long-term debt, net and finance leases increased to $2,510.8 million from $2,240.2 million at December 28, 2024.
03—Questions
Frequently Asked Questions
Why did GAAP earnings fall so sharply while non-GAAP earnings rose?
GAAP net income fell to $25.5 million ($0.50 per diluted share) from $67.3 million ($1.30) mainly due to lower revenue and higher amortization of intangible assets, which reached $65.3 million versus $32.6 million, including accelerated amortization of certain CDMO client relationships. A $0.15 per share loss from venture capital and strategic investments also weighed on GAAP results. Non-GAAP results exclude these items, and the increase was driven by a lower tax rate, lower interest expense and fewer diluted shares.
What changed in the 2025 guidance?
The company raised its reported revenue growth guidance to (5.5)% to (3.5)% from (7.0)% to (4.5)%, and organic revenue growth guidance to (4.5)% to (2.5)% from (5.5)% to (3.5)%. GAAP EPS guidance moved to $4.35 to $4.85 from $4.30 to $4.80, and non-GAAP EPS guidance to $9.30 to $9.80 from $9.10 to $9.60. The increase primarily reflects improved DSA net bookings in the first quarter.
How did each business segment perform?
Research Models and Services revenue was $213.1 million, down 3.5%, with organic revenue down 2.5% due to NHP shipment timing in China and lower Cell Solutions revenue. Discovery and Safety Assessment revenue was $592.6 million, down 2.1%, with organic revenue down 1.4%, driven by discovery services. Manufacturing Solutions revenue was $178.5 million, down 3.6%, with organic revenue down 2.2%, mainly from the CDMO and Biologics Testing businesses, and its GAAP operating margin was (4.8)%.
What are the main risks flagged in the filing?
The filing cites NHP supply constraints and U.S. government investigations into the Cambodia NHP supply chain, including the timing of resumed Cambodia NHP imports and potential DSA study delays. It also lists changes in the global economy, client R&D spending, currency and interest rate fluctuations, tax law changes, and the ability to integrate acquisitions such as Noveprim. Third-party legal costs tied to the NHP investigations were $11.0 million in DSA in the quarter.
How much capital did the company return to shareholders and how is its balance sheet changing?
The company repurchased 2.1 million shares for $350.0 million in the first quarter, with a cumulative total of 2.6 million shares under the $1.0 billion authorization and $549.3 million remaining as of March 29, 2025. Cash rose to $229.4 million, while long-term debt, net and finance leases increased to $2,510.8 million from $2,240.2 million, and total equity declined to $3,200.1 million from $3,466.9 million.
04—Continue